Avalo Therapeutics, Inc. Common Stock (AVTX) Stock Price
AVTXStock
$19.59+109.74%52W
Market Cap$1.05B
P/E—
PEG Ratio—
Div yield—
Beta0.63
AVTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)9.00%
Price vs S&P 500 (4W)6.99%
VGM Score34.54
AVTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.62 | -$0.83 | -34.52%(-$0.21) | |
| Q1 2026 | -$1.07 | -$0.98 | +8.55%(+$0.09) | |
| Q4 2025 | -$1.50 | -$0.37 | +75.25%(+$1.13) | |
| Q3 2025 | -$1.64 | -$2.19 | -33.70%(-$0.55) | |
| Q2 2025 | -$1.46 | -$1.92 | -31.73%(-$0.46) |
AVTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.37
4.40
4.43
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVTXAvalo Therapeutics, Inc. Common Stock | F | F | B | $19.59 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins to treat immune dysregulation disorders. The company's lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody targeting inflammatory diseases. Additional pipeline candidates include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).